An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate

Phase 2

Terminated

Brief Summary: Fermagate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.

The purpose of this study it to look at the safety of fermagate over longer periods of time.

Detailed Description: High levels of phosphate in the blood are linked with serious effects, due to calcium imbalances (high levels of parathyroid hormone (PTH), bone disease, formation of calcium deposits in the body, and blood-vessel disease).

This study is an open-label, multi-centre, single-group, 24-week study of fermagatebonate. Subjects participating in this study are those who took at least one dose of double-blind study medication in the IH 001 study and either completed study IH 001 or were withdrawn due to reasons other than an adverse event (AE) considered related to study treatment.

Recruitment & Eligibility

Inclusion Criteria

Taken at least one dose of double-blind medication during study IH 001 and either completed study IH 001 or were withdrawn due to reasons other than an AE considered related to study treatment
Male or female subjects on active haemodialysis, aged 18 years or over
Willing to abstain from taking any phosphate binder or oral magnesium-, aluminium-, or iron-containing products and preparations, other than the study medication;
Willing to avoid any intentional changes in diet such as fasting, dieting or overeating;
Willing to maintain their usual type and dose of Vitamin D supplementation.

Exclusion Criteria

Participation in any other clinical trial using an investigational product or device within the previous 4 months;
A significant history of alcohol, drug or solvent abuse in the opinion of the investigator;
Any disease or condition, physical or psychological, which in the opinion of the investigator would compromise the safety of the subject or increase the likelihood of the subject being withdrawn;
Clinically significant laboratory findings (for this subject population) in the opinion of the investigator.
Any malignancy with the exception of basal cell carcinoma;
A history of a motility disorder of the intestines, including, but not limited to, gastroparesis, ileus, pseudo-obstruction, megacolon, or mechanical obstruction;
A significant illness in the 4 weeks before screening;
Taking medication for seizures;
A history of haemochromatosis;
A history of serum ferritin concentration of ≥ 1000 ng/mL (excluding transient, treatment-induced ferritin elevation);
A history of dysphagia or swallowing disorders;
Female subjects who are lactating or pregnant. Women of childbearing potential (pre-menopausal and not surgically sterilised) unless they abstain from sexual intercourse or are using a reliable contraceptive method, that is, barrier methods, hormones or intrauterine device;
Current haemoglobin concentration of < 10.00 g/dL;
Allergy to the IMP or its constituents.

Arm && Interventions

Group	Intervention	Description
Fermagate	Fermagate	-

Primary Outcome Measures

Name	Time	Method
Assessment of AEs and other safety parameters	88 weeks

Secondary Outcome Measures

Name	Time	Method
Assessment of serum phosphate concentrations	88 weeks

Locations (15): 1614 West 42nd Street
🇺🇸
Pine Bluff, Arkansas, United States
US Renal Care
🇺🇸
Stuttgart, Arkansas, United States
Davita Dialysis Center
🇺🇸
Charlotte, North Carolina, United States
Southeast Renal Associates
🇺🇸
Charlotte, North Carolina, United States
Renal Unit, Birmingham Heartlands Hospital
🇬🇧
Birmingham, United Kingdom
St Lukes Hospital, Little Horton Lane
🇬🇧
Bradford, United Kingdom
Richard Bright Renal Unit, Southmead Hospital
🇬🇧
Bristol, United Kingdom
Addenbrookes Dialysis Centre, Addenbrookes Hospital
🇬🇧
Cambridge, United Kingdom
Renal Unit, Leicester General Hospital
🇬🇧
Leicester, United Kingdom
Dialysis Unit, Broad Green Hospital
🇬🇧
Liverpool, United Kingdom
Scroll for more (5 remaining)
1614 West 42nd Street
🇺🇸Pine Bluff, Arkansas, United States